Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial

被引:22
|
作者
Malizia, Velia [1 ]
Fasola, Salvatore [1 ,2 ]
Ferrante, Giuliana [3 ]
Cilluffo, Giovanna [1 ,2 ]
Montalbano, Laura [1 ,4 ]
Landi, Massimo [1 ,5 ]
Marchese, Donatella [1 ]
Passalacqua, Giovanni [6 ]
La Grutta, Stefania [1 ,3 ]
机构
[1] Univ Palermo, Inst Biomed & Mol Immunol, Natl Res Council Italy, Palermo, Italy
[2] Univ Palermo, Dept Econ Business & Stat Sci, Palermo, Italy
[3] Univ Palermo, Dept Sci Hlth Promot & Mother & Child Care, Palermo, Italy
[4] Univ Palermo, Dept Psychol, Palermo, Italy
[5] Natl Healthcare Syst, ASL TO3, Turin, Italy
[6] Univ Genoa, IRCCS San Martino, Allergy & Resp Dis, Dept Internal Med,IST, Genoa, Italy
关键词
Buffered hypertonic solution; Children; Nasal cytology; Quality of life; Nasal symptoms; Seasonal allergic rhinitis; QUALITY-OF-LIFE; MUCOCILIARY CLEARANCE; RHINOCONJUNCTIVITIS; ADOLESCENTS; ASTHMA; RELEVANCE; PH;
D O I
10.1159/000481093
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. Methods: In this 21-day, open-label, randomized controlled study, 36 SAR children (aged 6-13 years) with a Total 5 Symptom Score (T5SS) >= 5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. Results: BHS improved the T5SS total score to a greater extent than NSS (LSmc -6.45 vs. -5.45, p < 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc -0.76, p = 0.004) and eosinophils (LSmc -0.46, p = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc -0.57, p = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc -0.77, p = 0.025) and NSS (LSmc -1.39, p < 0.001) groups. Overall, BHS was well tolerated. Conclusions: In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life. (c) 2017 S. Karger AG, Basel
引用
收藏
页码:97 / 103
页数:7
相关论文
共 50 条
  • [41] Efficacy of Nasal Cellulose Powder in the Symptomatic Treatment of Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Trial
    Manuyakorn, Wiparat
    Klangkalya, Natchanun
    Kamchaisatian, Wasu
    Benjaponpitak, Suwat
    Sasisakulporn, Cherapat
    Jotikasthira, Wanlapa
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2017, 9 (05) : 446 - 452
  • [42] Efficacy of acupuncture at three nasal acupoints plus acupoint application for perennial allergic rhinitis: A multicenter, randomized controlled trial protocol
    Shou, Yin
    Hu, Li
    Zhang, Cuihong
    Xu, Shifen
    Jin, Qi
    Huang, Li
    Li, Bingrong
    Yuan, Long
    Xu, Siwei
    Zhang, Kaiyong
    Jiang, Huiru
    Zhang, Bimeng
    TRIALS, 2020, 21 (01)
  • [43] Isotonic saline nasal irrigation is an effective adjunctive therapy to intranasal corticosteroid spray in allergic rhinitis
    Nguyen, Shaun A.
    Psaltis, Alkis J.
    Schlosser, Rodney J.
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2014, 28 (04) : 308 - 311
  • [44] Efficacy, safety, and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults
    Raphael, Gordon D.
    Berger, William E.
    Prenner, Bruce M.
    Finn, Albert F., Jr.
    Kelley, Leith
    Tantry, Sudeesh K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (10) : 1329 - 1340
  • [45] Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis
    Gross, Gary N.
    Berman, Gary
    Amar, Niran J.
    Caracta, Cynthia F.
    Tantry, Sudeesh K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (06) : 630 - +
  • [46] A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray
    Graft, D
    Aaronson, D
    Chervinsky, P
    Kaiser, H
    Melamed, J
    Pedinoff, A
    Rosen, JP
    Schenkel, EJ
    Vandewalker, ML
    Keim, A
    Jensen, PK
    Nolop, K
    MesarinaWicki, B
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (04) : 724 - 731
  • [47] Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
    Zhang, Junyan
    Yang, Xiaobin
    Chen, Guangui
    Hu, Jintao
    He, Ying
    Ma, Jinxiang
    Ma, Zhaoen
    Chen, Huifang
    Huang, Yuyi
    Wu, Qiurong
    Liu, Yongping
    Yu, Lu
    Zhang, Hong
    Lai, He
    Zhang, Jianguo
    Zhai, Jinming
    Huang, Minqi
    Zou, Zehong
    Tao, Ailin
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (03) : 346 - 354.e1
  • [48] Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data
    Scadding, Glenis K.
    Keith, Paul K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2707 - 2715
  • [49] Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review
    Rodrigo, G. J.
    Neffen, H.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (02): : 160 - 170
  • [50] Efficacy of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) in Children With Allergic Rhinitis: A Randomized Controlled Trial
    Jeong, Kyunguk
    Jang, Seok Won
    Jeon, Se-Ah
    Seo, Hei Ji
    Kang, Se-Hui
    Han, Seung-Won
    Suh, Dong In
    Lee, Sooyoung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (40)